Celldex Therapeutics (CLDX) Short Interest Ratio & Short Volume $25.14 -0.24 (-0.95%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Celldex Therapeutics Short Interest DataCelldex Therapeutics (CLDX) has a short interest of 7.70 million shares. This marks a -1.66% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.5, indicating that it would take 6.5 days of the average trading volume of 891,722 shares to cover all short positions.Current Short Interest7,700,000 sharesPrevious Short Interest7,830,000 sharesChange Vs. Previous Month-1.66%Dollar Volume Sold Short$211.29 millionShort Interest Ratio6.5 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares66,344,000 sharesPercentage of Shares Shorted11.61%Today's Trading Volume2,166,760 sharesAverage Trading Volume891,722 sharesToday's Volume Vs. Average243% Short Selling Celldex Therapeutics? Sign up to receive the latest short interest report for Celldex Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCLDX Short Interest Over TimeCLDX Days to Cover Over TimeCLDX Percentage of Float Shorted Over Time Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Celldex Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20247,700,000 shares $211.29 million -1.7%N/A6.5 $27.44 11/15/20247,830,000 shares $184.40 million -5.0%N/A6.8 $23.55 10/31/20248,240,000 shares $214.73 million -1.9%N/A7.7 $26.06 10/15/20248,400,000 shares $246.96 million +1.1%N/A8.3 $29.40 9/30/20248,310,000 shares $282.46 million -1.2%N/A8.5 $33.99 9/15/20248,410,000 shares $371.39 million -1.9%N/A11.4 $44.16 Get the Latest News and Ratings for CLDX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20248,570,000 shares $354.20 million -1.0%N/A12.2 $41.33 8/15/20248,660,000 shares $286.65 million +3.1%N/A12.2 $33.10 7/31/20248,400,000 shares $320.12 million +13.7%N/A12.1 $38.11 7/15/20247,390,000 shares $292.27 million +5.7%N/A11.5 $39.55 6/30/20246,990,000 shares $258.70 million +8.7%N/A10.9 $37.01 6/15/20246,430,000 shares $222.93 million +2.6%N/A10.1 $34.67 5/31/20246,270,000 shares $208.79 million -5.3%N/A9.1 $33.30 5/15/20246,620,000 shares $265.93 million -5.3%N/A7.4 $40.17 4/30/20246,990,000 shares $261.57 million +3.6%N/A7.7 $37.42 4/15/20246,750,000 shares $263.72 million +2.9%N/A7.3 $39.07 3/31/20246,560,000 shares $275.32 million +11.2%N/A6.9 $41.97 3/15/20245,900,000 shares $247.86 million -8.0%N/A6.4 $42.01 2/29/20246,410,000 shares $308.06 million -7.6%N/A7.4 $48.06 2/15/20246,940,000 shares $255.39 million +3.4%N/A9.3 $36.80 1/31/20246,710,000 shares $236.33 million +7.9%N/A8.5 $35.22 1/15/20246,220,000 shares $261.49 million -5.6%N/A7.6 $42.04 12/31/20236,590,000 shares $261.36 million -10.3%N/A8.6 $39.66 12/15/20237,350,000 shares $273.05 million -8.9%N/A9.6 $37.15 11/30/20238,070,000 shares $243.79 million +2.4%N/A11.1 $30.21 11/15/20237,880,000 shares $224.82 million +40.2%N/A11.3 $28.53 10/31/20235,620,000 shares $132.18 million +0.9%N/A9.2 $23.52 10/15/20235,570,000 shares $145.60 million -3.3%N/A12.1 $26.14 9/30/20235,760,000 shares $158.52 million -5.4%N/A13.1 $27.52 9/15/20236,090,000 shares $170.22 million -3.3%N/A14.3 $27.95 8/31/20236,300,000 shares $175.77 million -3.7%N/A13.5 $27.90 8/15/20236,540,000 shares $205.55 million +8.5%N/A14.3 $31.43 7/31/20236,030,000 shares $213.22 million -3.8%N/A13.8 $35.36 7/15/20236,270,000 shares $233.81 million +1.8%N/A13.5 $37.29 6/30/20236,160,000 shares $209.01 million +2.7%N/A11 $33.93 6/15/20236,000,000 shares $221.22 million +3.5%N/A9.8 $36.87 5/31/20235,800,000 shares $184.44 million +7.0%N/A9.3 $31.80 5/15/20235,420,000 shares $185.69 million +1.1%N/A8.4 $34.26 4/30/20235,360,000 shares $168.52 million +3.5%N/A8.4 $31.44 4/15/20235,180,000 shares $156.90 million -1.7%N/A8.6 $30.29Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem 3/31/20235,270,000 shares $189.61 million +38.0%N/A9.9 $35.98 3/15/20233,820,000 shares $167.13 million +5.5%N/A8 $43.75 2/28/20233,620,000 shares $154.90 million +4.3%N/A7.5 $42.79 2/15/20233,470,000 shares $148.79 million +4.5%N/A7.7 $42.88 1/31/20233,320,000 shares $146.28 million -4.3%N/A6.8 $44.06 1/15/20233,470,000 shares $159.69 million +1.8%N/A7 $46.02 12/30/20223,410,000 shares $151.98 million -17.2%N/A6.8 $44.57 12/15/20224,120,000 shares $182.47 million +1.7%N/A8 $44.29 11/30/20224,050,000 shares $150.21 million -1.9%N/A9 $37.09 11/15/20224,130,000 shares $151.53 million -8.2%N/A9 $36.69 10/31/20224,500,000 shares $158.09 million -0.9%N/A9.7 $35.13 10/15/20224,540,000 shares $142.74 million -1.5%N/A9.3 $31.44 9/30/20224,610,000 shares $129.59 million +2.4%N/A9 $28.11 9/15/20224,500,000 shares $136.40 million +2.3%N/A6.2 $30.31 8/31/20224,400,000 shares $133.76 million +4.0%N/A5.6 $30.40 8/15/20224,230,000 shares $158.92 million +14.3%N/A5.1 $37.57 7/31/20223,700,000 shares $113.66 million -2.9%30.7%4.3 $30.72 7/15/20223,810,000 shares $111.79 million -0.3%31.6%4.5 $29.34 6/30/20223,820,000 shares $102.99 million -18.9%31.7%4.7 $26.96 6/15/20224,710,000 shares $104.99 million +1.5%39.0%7.3 $22.29 5/31/20224,640,000 shares $109.13 million -5.5%N/A8 $23.52 5/15/20224,910,000 shares $147.25 million -1.0%N/A8.7 $29.99 4/30/20224,960,000 shares $151.53 million -9.3%N/A9 $30.55 4/15/20225,470,000 shares $196.04 million -0.2%N/A9.8 $35.84 3/31/20225,480,000 shares $186.65 million -8.7%N/A9.3 $34.06 3/15/20226,000,000 shares $187.26 million +3.3%N/A10.3 $31.21 2/28/20225,810,000 shares $173.72 million +11.7%N/A10 $29.90 2/15/20225,200,000 shares $169.78 million +2.4%N/A9.4 $32.65 1/31/20225,080,000 shares $157.53 million +3.3%N/A9.9 $31.01 1/15/20224,920,000 shares $157.00 million +3.1%N/A0 $31.91 12/31/20214,770,000 shares $184.31 million +9.9%N/A10.6 $38.64 12/15/20214,340,000 shares $166.92 million +6.6%N/A10.1 $38.46 11/30/20214,070,000 shares $155.07 million +12.4%N/A9.7 $38.10 11/15/20213,620,000 shares $155.70 million -2.7%N/A8.2 $43.01 10/29/20213,720,000 shares $158.25 million +25.7%N/A7.9 $42.54 10/15/20212,960,000 shares $136.69 million -0.7%N/A5.7 $46.18 9/30/20212,980,000 shares $160.89 million -11.0%N/A3.8 $53.99 9/15/20213,350,000 shares $178.25 million -15.4%N/A3.7 $53.21 8/31/20213,960,000 shares $208.49 million -8.1%N/A4.4 $52.65 8/13/20214,310,000 shares $188.43 million +15.2%N/A4.9 $43.72 7/30/20213,740,000 shares $163.63 million +11.6%N/A4.5 $43.75 7/15/20213,350,000 shares $146.93 million +19.2%N/A4.2 $43.86 6/30/20212,810,000 shares $93.97 million +11.1%7.3%4.1 $33.44 6/15/20212,530,000 shares $73.88 million -18.4%6.6%4.4 $29.20 5/28/20213,100,000 shares $86.65 million -3.7%8.1%5.3 $27.95 5/14/20213,220,000 shares $80.53 million -3.0%N/A5.2 $25.01 4/30/20213,320,000 shares $103.82 million -3.8%N/A5 $31.27 4/15/20213,450,000 shares $76.83 million -3.1%N/A4.9 $22.27 3/31/20213,560,000 shares $70.24 million +24.9%N/A4.9 $19.73 3/15/20212,850,000 shares $72.33 million -0.7%N/A4.3 $25.38Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem 2/26/20212,870,000 shares $78.95 million -16.6%N/A4.4 $27.51 2/12/20213,440,000 shares $81.70 million -2.0%N/A4.9 $23.75 1/29/20213,510,000 shares $72.80 million -1.7%N/A5.2 $20.74 1/15/20213,570,000 shares $64.19 million -25.8%N/A5.6 $17.98 12/31/20204,810,000 shares $86.00 million +118.6%N/A7.9 $17.88 12/15/20202,200,000 shares $40.13 million -9.5%N/A3 $18.24 11/30/20202,430,000 shares $55.28 million -13.8%N/A3.4 $22.75 11/15/20202,820,000 shares $56.32 million -5.4%N/A4.1 $19.97 10/30/20202,980,000 shares $45.83 million -8.0%N/A4.5 $15.38 10/15/20203,240,000 shares $52.91 million -1.5%N/A4.6 $16.33 9/30/20203,290,000 shares $48.79 million +9.7%N/A4.3 $14.83 9/15/20203,000,000 shares $35.19 million +23.5%N/A4.4 $11.73 8/31/20202,430,000 shares $29.01 million +102.5%N/A0.9 $11.94 8/14/20201,200,000 shares $12.37 million +52.5%N/A0.4 $10.31 7/31/2020787,000 shares $8.10 million -17.3%N/A0.3 $10.29 7/15/2020951,200 shares $10.21 million -37.8%N/A0.3 $10.73 6/30/20201,530,000 shares $19.89 million -33.8%N/A0.6 $13.00 6/15/20202,310,000 shares $24.74 million +668.2%N/A0.9 $10.71 5/29/2020300,700 shares $796,855.00 +13.8%N/A0.7 $2.65 5/15/2020264,200 shares $597,092.00 -13.9%N/A0.7 $2.26 4/30/2020306,700 shares $751,415.00 -2.6%N/A0.7 $2.45 4/15/2020314,900 shares $588,863.00 -2.4%N/A0.8 $1.87 3/31/2020322,500 shares $970,725.00 -22.3%N/A1 $3.01 3/13/2020415,100 shares $751,331.00 +8.9%N/A2.1 $1.81 2/28/2020381,100 shares $594,516.00 +56.1%N/A1.3 $1.56 2/14/2020244,100 shares $539,461.00 -8.2%N/A0.9 $2.21 1/31/2020266,000 shares $694,260.00 -6.3%N/A1.9 $2.61 1/15/2020283,900 shares $652,970.00 -8.4%N/A1.8 $2.30 12/31/2019309,800 shares $709,442.00 -11.7%N/A2.1 $2.29 CLDX Short Interest - Frequently Asked Questions What is Celldex Therapeutics' current short interest? Short interest is the volume of Celldex Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 7,700,000 shares of CLDX short. Learn More on Celldex Therapeutics' current short interest. What is a good short interest ratio for Celldex Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CLDX shares currently have a short interest ratio of 6.0. Learn More on Celldex Therapeutics's short interest ratio. Which institutional investors are shorting Celldex Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Celldex Therapeutics: Jane Street Group LLC, Ikarian Capital LLC, Walleye Capital LLC, Valence8 US LP, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Celldex Therapeutics' short interest increasing or decreasing? Celldex Therapeutics saw a drop in short interest during the month of November. As of November 30th, there was short interest totaling 7,700,000 shares, a drop of 1.7% from the previous total of 7,830,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Celldex Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biotechnology" compare to Celldex Therapeutics: Madrigal Pharmaceuticals, Inc. (19.62%), Halozyme Therapeutics, Inc. (6.81%), Ionis Pharmaceuticals, Inc. (7.18%), Alkermes plc (8.63%), Amicus Therapeutics, Inc. (6.97%), Ligand Pharmaceuticals Incorporated (4.16%), Geron Co. (10.98%), MannKind Co. (15.61%), Dynavax Technologies Co. (13.62%), BioCryst Pharmaceuticals, Inc. (9.35%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Celldex Therapeutics stock? Short selling CLDX is an investing strategy that aims to generate trading profit from Celldex Therapeutics as its price is falling. CLDX shares are trading down $0.24 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Celldex Therapeutics? A short squeeze for Celldex Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CLDX, which in turn drives the price of the stock up even further. How often is Celldex Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CLDX, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies MDGL Short Interest Data HALO Short Interest Data IONS Short Interest Data ALKS Short Interest Data FOLD Short Interest Data LGND Short Interest Data GERN Short Interest Data MNKD Short Interest Data DVAX Short Interest Data BCRX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CLDX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDX Stock Alerts